Form D · Biotechnology

Esperance Pharmaceuticals, Inc

Houston, TX · CIK 0001451464

Offering snapshot reported Jul 12, 2019 · SEC filing

Reported sold
$1M
Offering amount: $1M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 28, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 12, 2019Initial$1,000,000No comparison1SEC filing
Jun 9, 2011Initial$5,733,626No comparison10SEC filing
May 3, 2010Amendment$9,000,000No comparison3SEC filing
May 3, 2010Amendment$3,700,245No comparison5SEC filing
Nov 26, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Nov 24, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-344116

Source: Form D, filed Jul 12, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Hector Alila Director, Executive
Richard Babb Executive
Ross Barrett Director
Sonia Deggs Executive
Peter Hoang Director
Carola Leuschner Executive
Joseph Lovett Director
Chad Souvignier Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Two Houston Center 909 Fannin, Suite 2000
Houston, TX, 77010